HC Wainwright Has Bullish Estimate for DBVT FY2025 Earnings

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of DBV Technologies in a research note issued on Monday, May 5th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.15) per share for the year, up from their previous estimate of ($5.45). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share.

Several other brokerages have also issued reports on DBVT. JMP Securities lifted their price target on shares of DBV Technologies from $10.00 to $15.00 and gave the company a "market outperform" rating in a report on Thursday, May 1st. StockNews.com began coverage on DBV Technologies in a research note on Thursday, May 1st. They issued a "hold" rating for the company.

DBV Technologies Stock Up 1.2 %

Shares of DBV Technologies stock opened at $9.50 on Thursday. The firm's 50-day moving average price is $6.68 and its two-hundred day moving average price is $4.78. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $9.90. The company has a market capitalization of $260.21 million, a price-to-earnings ratio of -2.11 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The business had revenue of $0.51 million for the quarter.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.